Abstract
AbstractThe traditional, surgery-first approach for colon cancer is increasingly challenged by our evolving understanding of tumor biology and a growing number of measurable tumor features that can help guide contemporary treatment plans. Certain tumor characteristics now make it practical to challenge locally advanced colon cancer with neoadjuvant chemotherapy or immunotherapy, and allow for targeted postoperative therapies. The contemporary data supporting these tailored approaches to integrating systemic therapy before or after resection are summarized in this article.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call